All In Biotech

Drug Trial Radar · NCT07796646

Study to Evaluate the Long-Term Safety of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

An Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Ultevursen in Participants With Retinitis Pigmentosa (RP) Due to Mutations in Exon 13 of the USH2A Gene

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

81

Planned (sponsor's estimate)

Start

Oct 5, 2026

Primary completion

Feb 28, 2030

Study completion Mar 2030

Sponsor

Lead sponsor
Laboratoires TheaIndustry
Sponsor type
Industry
Collaborators
Sepul Bio
First posted
Sep 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 8 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this Phase 2 Open-label study is to evaluate the long-term safety and tolerability of Ultevursen administered via intravitreal injection (IVT) in participants with Retinitis Pigmentosa due to mutations in exon 13 of the USH2A gene. This is a multicenter study which will enroll approximately 81 participants, however, the exact number enrolled will depend on the final number completing the 24-month LUNA trial and are eligible and willing to enroll in CAPELLA.

Conditions

  • Retinitis Pigmentosa (RP)
  • Usher Syndrome Type 2
  • Deaf Blind
  • Retinal Disease
  • Eye Diseases, Hereditary
  • Eye Disorders Congenital
  • Vision Disorders

Interventions

  • No intervention, will not receive any active study interventionOther

    Observation only (no experimental drug administered)

  • Intravitreal Injection of UltevursenDrug

    Participants will receive up to 4 doses over a 24-month period

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of ocular adverse events (AEs), including serious AEs (SAEs) and adverse events of special interest (AESI)Time frame: 24 Months
  2. Incidence and severity of non-ocular AEs, including SAEs.Time frame: 24 Months

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.